Mechanisms of immunomodulation by glatiramer acetate
- 12 December 2000
- journal article
- Published by Wolters Kluwer Health in Neurology
- Vol. 55 (11) , 1704-1714
- https://doi.org/10.1212/wnl.55.11.1704
Abstract
Objective: To define the mechanism of action of glatiramer acetate (GA; formerly known as copolymer-1) as an immunomodulatory treatment for MS. Background: The proposed mechanisms of action of GA include 1) functional inhibition of myelin-reactive T cells by human leukocyte antigen (HLA) blocking, 2) T-cell receptor (TCR) antagonism, and 3) induction of T helper 2 (Th2) immunomodulatory cells. In this report, the authors examined the effects of GA on the functional activation of human T-cell clones (TCC) specific for myelin basic protein (MBP) and for foreign antigens. Several questions were addressed: Is the inhibitory effect of GA specific for autoantigens? Is it mediated by blocking the interaction between peptide and HLA molecule? Is GA a partial agonist or TCR antagonist, or does it induce anergy? Does it induce Th2 modulatory T cells? Methods: The effects of GA on antigen-induced activation of human TCC specific for MBP, influenza virus hemagglutinin, and Borrelia burgdorferi were studied by proliferation and cytokine measurements, TCR downmodulation, and anergy assays. GA-specific TCC were generated in vitro from the peripheral blood of patients and healthy controls by limiting dilution. Results: GA more strongly inhibited the proliferation of MBP, as compared with foreign antigen-specific TCC; in some MBP-specific TCC, the production of Th1-type cytokines was preferentially inhibited. In addition to HLA competition, the induction of anergy, but not direct TCR antagonism, was observed. Numerous GA-specific TCC were generated from the peripheral blood of both MS patients and normal controls, and a fraction of these showed a Th2 phenotype. Conclusions: This study confirms a preferential inhibitory effect of GA on autoreactive TCC. With respect to cellular mechanisms, although HLA competition appears to play the most important role in functional inhibition in vitro, a direct effect on the TCR may be involved at least in some autoreactive T cells as shown by anergy induction. Although not confirmed at the clonal level, it is demonstrated further that GA induces T cells that crossreact with myelin proteins. GA-specific, Th2-modulatory cells may play an important role in mediating the effect of the drug in vivo.Keywords
This publication has 39 references indexed in Scilit:
- Repertoire Breadth of Human CD4+ T Cells Specific for HIV gp120 and p66 (Primary Antigens) or for PPD and Tetanus Toxoid (Secondary Antigens)Human Immunology, 1998
- INDUCTION OF TH1 AND TH2 CD4+T CELL RESPONSES:The Alternative ApproachesAnnual Review of Immunology, 1997
- An altered peptide ligand mediates immune deviation and prevents autoimmune encephalomyelitisImmunity, 1995
- Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosisNeurology, 1995
- Induction of T-cell anergy by altered T-cell-receptor ligand on live antigen-presenting cellsNature, 1993
- Antigen analog-major histocompatibility complexes act as antagonists of the T cell receptorCell, 1992
- Antigen-driven bystander suppression after oral administration of antigens.The Journal of Experimental Medicine, 1991
- A Pilot Trial of Cop 1 in Exacerbating–Remitting Multiple SclerosisNew England Journal of Medicine, 1987
- Suppression of experimental allergic encephalomyelitis in rhesus monkeys by a synthetic basic copolymerClinical Immunology and Immunopathology, 1974
- Suppression of experimental allergic encephalomyelitis by a synthetic polypeptideEuropean Journal of Immunology, 1971